GSK plc ADR Stock
Price
Target price
€38.20
€38.20
0.000%
-
0.000%
€35.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc ADR Stock
The GSK plc ADR price is unchanged compared to yesterday.
Currently there is a rather positive sentiment for GSK plc ADR with 4 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 35 € is below the current price of 38.2 € for GSK plc ADR, so the potential is actually -8.38%.
So far the community has only identified positive things for GSK plc ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of GSK plc ADR in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
GSK plc ADR | 0.000% | 3.243% | -4.020% | 13.018% | 13.690% | -2.051% | -14.422% |
Astrazeneca ADR | 0.710% | 8.527% | 14.754% | 1.449% | 13.821% | 61.663% | - |
Bayer AG ADR | -3.790% | -1.493% | -3.650% | -55.705% | -23.256% | -51.111% | -58.228% |
Novo Nordisk A/S ADR | 0.850% | 1.732% | -1.674% | -23.701% | 25.267% | 90.129% | 169.495% |
Comments
GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
News
GSK is a remedy for the winter investment blahs
GSK (NYSE: GSK) is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to